We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 8% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%.
“Companion animal revenue decreased 8%, reflecting macro-driven price sensitivity and competitive pressure in dermatology, as well as generic competition.”
−3Long-term trend
| Since its Dec 2021 high | Down 67% |
| Latest filing | 8-K, Nov 5 |
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
After its last 4 reports it closed -7.0% on average, higher 1 of 4 times.
ZTS is #35 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 35 |
Share count against a year before: ZTS -7.1%, ELAN +0.6%, PFE +0.3%.
Expected to report Thu Feb 11, before the open (in 93 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $2.4B, 1% less than a year ago; a profit of $1.44 a share, from $1.63.
“Companion animal revenue decreased 8%, reflecting macro-driven price sensitivity and competitive pressure in dermatology, as well as generic competition.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Companion Animal | $1.6B | $1.7B | $1.6B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| Revenue | $9.22B to $9.32B |
Sales grew 7.2% a year over 5 years, fiscal 2020 to 2025.
Pays $2.12 a share a year.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -4.8% | -8.0% | not yet |
| Aug 6, 2026 | +6.0% | +3.9% | -1.1% |
| May 7, 2026 | -18.5% | -21.5% | -33.2% |
Sales grew every year from 2018 to 2025, to $9.5B. It made a profit in each of the eight years.
RSI 56.3, MACD below signal, above its 50-day, below its 200-day. Not scored.
Its dividends come to 40% of its free cash flow.
| Dividend | $2.12 a share a year |
| Paid out | About $886M a year |
| Free cash flow | $2.2B |
| Record | Raised every year since 2013 |
42 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ZTS is 0.2% of DGRO, 0.1% of VIG, and 0.1% of VYM, the most of the 24 funds Breakaway covers, by their holdings as filed for Jul 31, 2026.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
“Although our business is the largest based on revenue in the animal health industry (which includes medicines, vaccines and diagnostics), we face competition in the regions in which we compete.”
ZTS scores 6 today, which Breakaway calls Average. It is #35 of 90 in Pharma by Quality Score, with 4 of 14 chart checks firing. Down 8% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ZTS scores 6 today, which Breakaway calls Average (6 to 10). That is #35 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZTS's 6.
Expected to report Thu Feb 11, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ZTS closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.